Current status of agents active against the T315I chronic myeloid leukemia phenotype

Author： Burke Aine Carol Swords Ronan T Kelly Kevin Giles Francis J

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.16, Iss.1, 2011-03, pp. : 85-103

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34⁺ cells

By Santucci Maria Mancini Manuela Corradi Valentina lacobucci Ilaria Martinelli Giovanni Botta Maurizio Schenone Silvia

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 876-878

Springer Publishing Company

Access to resources Recommend Favorite

New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms

Current Medicinal Chemistry, Vol. 17, Iss. 13, 2010-05 ,pp. : 1220-1245

Bentham Science Publishers

Access to resources Recommend Favorite

Stem Cell Transplantation for Chronic Myeloid Leukemia (CML): Current Indications and Perspectives

Current Cancer Drug Targets, Vol. 13, Iss. 7, 2013-01 ,pp. : 775-778

Bentham Science Publishers

Access to resources Recommend Favorite

Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations

By Haznedaroglu Ibrahim C

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 15, 2013-10 ,pp. : 2005-2010

Informa Healthcare

Access to resources Recommend Favorite

Treatment options for chronic myeloid leukemia

By Tanaka Maria Florencia Kantarjian Hagop Cortes Jorge Ohanian Maro Jabbour Elias

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 6, 2012-04 ,pp. : 815-828

Informa Healthcare

Access to resources Recommend Favorite